 Evogene Ltd. NASDAQ: EVGN TASE: EVGN, a leading biotechnology company aiming to revolutionize the development of novel products for life-science based industries, announced today that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2019 with the U.S. Securities and Exchange Commission the SEC. 